Targeting KRAS

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• KRAS mutations, particularly KRASG12V, are key drivers in solid tumors like pancreatic and colorectal cancers.
• TCR-engineered T cells offer a targeted cancer therapy approach, but HLA restriction limits their application in diverse populations.
• Developing HLA-specific TCRs is crucial for effective cancer immunotherapy, especially in underrepresented ethnic groups.

Purpose of the Study:

• To identify and characterize a KRASG12V-specific T cell receptor (TCR) for potential cancer immunotherapy.
• To evaluate the efficacy of TCR-engineered CD4+ T cells targeting KRASG12V in preclinical models.
• To address the HLA restriction limitations of TCR-based therapies in the Chinese population.

Main Methods:

• Identification of a KRASG12V-specific TCR from a colorectal cancer patient.
• Engineering CD4+ T cells with the identified TCR for KRASG12V targeting.
• In vitro and in vivo efficacy studies using antigen-presenting cells (APCs) and xenograft mouse models.
• HLA subtype identification through IFN-γ secretion assays.

Main Results:

• A novel KRASG12V-specific TCR recognizing Class II MHC was identified.
• TCR-engineered CD4+ T cells, not CD8+ T cells, demonstrated significant anti-tumor efficacy in vitro and in vivo.
• The TCR specifically targets KRASG12V presented by HLA-DPB1*03:01 and DPB1*14:01, offering broad applicability in the Chinese population.

Conclusions:

• TCR-engineered CD4+ T cells targeting KRASG12V are a viable therapeutic strategy for solid tumors.
• The identified TCR, restricted by HLA-DPB1*03:01 and DPB1*14:01, overcomes HLA barriers for Chinese patients.
• This TCR holds significant promise for precision immunotherapy in solid tumors.